$HQY

Ladd Delano sold $675K of HQY

Ladd Delano (EVP, General Counsel) sold 7,500 shares of HEALTHEQUITY, INC. (HQY) at $90.00 ($0.68M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ladd Delano
Published Jun 1, 2026, 10:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
medium confidence
Mentioned
$HQY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The main tradable element is the disclosed sale size and the fact it was executed under a pre-arranged plan, which generally lowers interpretive impact.

02

Market read

Routine insider selling disclosure for HQY; sentiment impact is likely limited due to 10b5-1 pre-arrangement.

03

What to watch

Traders may over-weight single insider sales; the more informative signal would be repeated insider selling across multiple officers or changes in buying/selling patterns outside 10b5-1.

Relevance 6/10Novelty 6/10Timing: Filed June 1; sale occurred May 28 (post-disclosure timing for traders).

Background

The article is an SEC Form 4 insider transaction disclosure (open-market sale) by an HQY executive, including whether it was pre-arranged under Rule 10b5-1.

Company-level read

Ticker impact

$HQYNeutralMedium confidence
Context

SEC Form 4 shows HQY EVP & General Counsel Ladd Delano sold 7,500 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived unless followed by additional insider activity or fundamental news.

Evidence & confidence

The filing is a routine insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider disclosure without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the disclosure may be largely mechanical and not meaningfully bearish.

Key entities

  • HEALTHEQUITY, INC.

    Company whose shares were sold by an insider; subject of the SEC Form 4 disclosure.

  • Ladd Delano

    EVP, General Counsel at HEALTHEQUITY; reported open-market sale of 7,500 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HQYHighAI 8/10

HealthEquity (HQY) Q2 2027 Earnings Call Transcript

HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.

$HQYMed

Why HealthEquity Stock Sank This Week

HealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.